News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–64
Matches
64
Sources here
12
Companies here
1
Search results Stored financial headlines

Active search

64 matching headlines

Ticker or company: ADPTMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies (Nasdaq: ADPT) boosts MRD 2026 guidance after Q2 revenue hits $71.6M

Adaptive Biotechnologies (ADPT) announced strong second-quarter 2026 results, with total revenue reaching $71.6 million, a 22% year-over-year increase, primarily driven by its Minimal Residual Disease (MRD) segment which grew 33%. The company raised its full-year 2026 MRD revenue guidance to $268–$278 million and completed …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
WKYC Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies: Q2 Earnings Snapshot

This article provides an earnings snapshot for Adaptive Biotechnologies (NASDAQ: ADPT) for its second quarter. The content appears to be a placeholder or an incomplete article, as it lacks any financial data, results, or detailed information beyond the title.

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis

Adaptive Biotechnologies Corp (ADPT) has a current financial score of 7.62, ranking 97 out of 386 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $70.87 million, marking a 35.14% …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Adaptive Biotechnologies Corp (ADPT), listing its major shareholders and their respective proportions, with Viking Global Investors LP holding the largest share. It also categorizes shareholders by type and provides a historical overview of institutional shareholding and recent …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) Cash Flow

This article provides a comprehensive overview of Adaptive Biotechnologies Corp (ADPT)'s cash flow statements, including operating, investing, and financing activities. It presents detailed quarterly and annual financial data, highlighting key metrics like operating cash flow, capital expenditures, and free cash flow. The article also …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a revenue breakdown for Adaptive Biotechnologies Corp (ADPT), detailing its financial performance by business segments. It shows that MRD revenue accounts for 76.66% ($212.33M) and Immune medicine revenue for 23.34% ($64.64M). The article also indicates the current stock price and market …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Adaptive Biotechnologies Corp (ADPT), highlighting its current earnings forecast score, average price target, and analyst ratings. It includes peer comparisons and answers frequently asked questions regarding revenue expectations, price targets, and past EPS performance. The consensus among …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

ADPT|Adaptive Biotechnologies Corp|Price:24.455|Chg%:-0.795

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

ADPT|Adaptive Biotechnologies Corp|Price:22.270|Chg%:-0.040

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies Corp. Revenue Breakdown – HAM:1HM

Adaptive Biotechnologies Corp. (HAM:1HM) generated €235.82 million in revenue last year, primarily from its Minimal Residual Disease - Service segment, which contributed €164.18 million. The majority of its revenue, €235.82 million, came from the United States.

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies (ADPT) Stock May Be 22% Undervalued As Growth Hopes Build

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Adaptive Biotechnologies stock has delivered very strong total returns over the past three years, while its valuation signals are pulling in different directions, with the Discounted Cash …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In

Adaptive Biotechnologies (ADPT) has shown strong recent stock momentum with significant returns over the past three months and year, driven by improved loss forecasts and revenue growth. While some analysts view the stock as overvalued at $22.31 compared to a $20.14 fair value based …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies CSO Harlan Robins sells $10.78m in stock

Harlan S. Robins, CSO of Adaptive Biotechnologies Corp, sold approximately $10.78 million worth of company stock on July 21, 2026, after exercising stock options. These sales, conducted under a Rule 10b5-1 trading plan, occurred when the stock was near its 52-week high and followed …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 4 Adaptive Biotechnologies Corp For: 23 July By Investing.com

This article reports on a Form 4 filing for Adaptive Biotechnologies Corp (ADPT) for activity on July 23. It states that the information was published on July 24, 2026, at 01:06, and includes details about its stock performance, showing a slight increase of 0.22%. …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) CSO exercises options and sells 492,400 shares

Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, recently exercised stock options for 284,800 shares and subsequently sold 492,400 common shares. These transactions, executed under a Rule 10b5-1 trading plan, involved shares sold at weighted-average prices of $21.72 and $22.12. Following these trades, …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stocktwits Earnings Main company 🇺🇸 United States

ADPT: Adaptive Biotechnologies Corp Latest Stock Price, Analysis, News and Trading Ideas

This page provides real-time stock information, analysis, news, and trading ideas for Adaptive Biotechnologies Corp (ADPT). It includes current stock price, market cap, volume, 52-week high/low, PE ratio, and upcoming earnings dates. The page also features recent news articles related to ADPT's earnings expectations …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall St. Earnings Main company 🇺🇸 United States

Will Earnings Estimate Upgrades and a Smaller Projected Loss Change Adaptive Biotechnologies' (ADPT) Narrative?

Adaptive Biotechnologies (ADPT) recently received a Zacks Rank #2 (Buy) upgrade due to upward revisions in earnings estimates and expectations for a smaller projected loss and higher revenue for Q2 2026. This positive outlook is driven by improving business trends and strong performance in …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended June 2026, with an anticipated loss of $0.13 per share. The company currently holds a Zacks Rank #2, but its Earnings ESP of 0% suggests …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

ADPT (ADPT) Form 144 shows Harlan Robins planning sizable stock sale

Harlan Robins, an insider at Adaptive Biotechnologies Corp (ADPT), has filed a Form 144 indicating a planned sale of common stock through Goldman Sachs & Co. LLC, with an anticipated transaction date of July 21, 2026. The filing details securities information including figures of …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Analyst action Main company 🇺🇸 United States

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

Adaptive Biotechnologies (ADPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Revenue Growth Amidst Valuation Challenges

Adaptive Biotechnologies Corp (ADPT) shows significant revenue growth of 35.10% driven by its immune medicine platform and clonoSEQ diagnostic test, yet faces profitability challenges with a negative EPS and ROE. Despite current unprofitability, investor sentiment is largely optimistic, with analysts setting a price target …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 5,000 shares in plan

Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), sold 5,000 shares of common stock on July 16, 2026, at a price of $23.00 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted on December 16, 2025. Following …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Market update Main company 🇺🇸 United States

Adaptive Biotechnologies CPO Lo reports $2.39m stock sale

Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold approximately $2.39 million worth of company stock on July 15, 2026, executed under a Rule 10b5-1 trading plan. This transaction involved selling 105,762 shares at a weighted average price of $22.59, while simultaneously acquiring the same …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares

Adaptive Biotechnologies Corp's Chief People Officer, Francis Lo, exercised 105,762 stock options with various strike prices and subsequently sold all 105,762 common shares at a weighted average price of $22.59 on July 15, 2026. These transactions, conducted under a Rule 10b5-1 trading plan adopted …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Canada Market update Main company 🇺🇸 United States

Form 4 Adaptive Biotechnologies Corp For: 17 July By Investing.com

This article reports on a Form 4 filing for Adaptive Biotechnologies Corp on July 17. Form 4s are filed with the SEC whenever there is a material change in the holdings of company insiders. The content is very brief, stating only the company and …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT)

Susan Bobulsky plans to sell 5,000 shares of Adaptive Biotechnologies Corp (ADPT) common stock, valued at $114,500, with a planned sale date of July 16, 2026. The shares originate from previously exercised stock options and will be sold through Morgan Stanley Smith Barney LLC …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Adaptive Biotechnologies stock hits 52-week high at 22.81 USD

Adaptive Biotechnologies (NASDAQ: ADPT) stock reached a new 52-week high of $22.81, reflecting a 108.77% increase over the past year. This surge is supported by strong revenue growth and investor confidence in the company's biotechnology focus, despite an InvestingPro analysis suggesting potential overvaluation. The …

ADPT main company
Sharemaestro market context Trend signal active 52 weeks +90.3% · Next-week setup positive 58.0% ADPT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context